This technology is a vector plasmid that induces internalizing RGD (iRGD) peptide in vivo for the reduction of solid tumors.
Current methods to treat solid tumors often face significant challenges in penetrating cancer cells. Small molecular chemotherapeutics, immune checkpoint blockade drugs, and cellular immunotherapies exist, but often fail to achieve optimal efficacy due to their inability to penetrate. Additionally, solid tumors are often immunosuppressive and chemotherapy-resistant in nature. There is a need for a therapeutic that not only reduces the immunosuppressive environment around solid tumors but also boosts the efficiency of penetration for other therapies.
This technology is a plasmid vector that encodes iRGD peptide to reduce immunosuppressive environments in solid tumors by limiting fibrosis, angiogenesis, hypoxia, the presence of regulatory T cells, and metastasis. The vector can be engineered to express in chimeric antigen receptor (CAR) T cells and subsequently expressed and secreted by various cancer cell lines, thereby producing a steady supply of iRGD at the tumor site without the need for multiple injections. Additionally, when co-administered, the technology can increase the tumor's susceptibility to other anti-tumor therapies. This technology is a long-term cancer therapy that can be used as a monotherapy or in combination with other therapies.
This technology has been validated on CAR-T cells and human cancer cell lines.
Patent Pending
IR CU26114, CU25212, CU25214, CU26107
Licensing Contact: Jerry Kokoshka